Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine

Overcoming Oral Oncolytic Challenges
December 5, 2017
Hepatocellular carcinoma risk unclear after hepatitis C treatment
December 5, 2017
Show all

Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine

The medication cladribine, used early, might benefit those with multiple sclerosis.

Patients with multiple sclerosis treated with cladribine tablets for 2 years followed by placebo for an additional 2 years experience similar clinical benefits and lower risk for clinical worsening compared with patients treated with cladribine only for all 4 years, according to findings of an extension study published in Multiple Sclerosis Journal.

In this extension study of the CLARITY trial, a total of 806 patients with normal lymphocyte counts were provided a new treatment regimen. Participants who received placebo in the CLARITY trial now received 3.5 mg/kg cladribine tablets, whereas those who previously received cladribine were randomly assigned to either 3.5 mg/kg cladribine tablets or placebo.

Patients receiving cladribine tablets had higher lymphopenia grade ≥3 rates than the placebo group; however, overall adverse events were similar between groups.

Read full article: Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine

Read Full Article: Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.